AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyNot reportedPublished in a peer-reviewed journal
Ocrelizumab in Individuals with MS: Wearing Off Phenomenon
In a study of 528 individuals with MS receiving ocrelizumab, wearing off was observed in 24.8% of participants. Predictors included obesity, fatigue, and reliance on assistive devices. Interventions improved or resolved symptoms in over 80% of those affected.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
Understanding the prevalence and predictors of the wearing-off phenomenon can guide future management strategies for individuals on ocrelizumab.
What this does not prove
The study may not fully capture all factors related to wearing off due to its reliance on self-reported symptoms and clinical records.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 528 · number of people with MS receiving ocrelizumab
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2025-11-03
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Individuals with MS receiving ocrelizumab
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceOcrelizumab Wearing-Off Phenomenon: Prevalence, Predictors, and Outcomes After Intervention. ↗DOI: 10.7224/1537-2073.2024-092
Supporting passages (10)
sample size528
sample size basisCONCLUSIONS: Wearing off was observed in nearly a quarter of people with MS receiving ocrelizumab.
publication date2025-11-03
interventionAny intervention, such as shortening ocrelizumab infusion intervals or switching therapies, improved or resolved wearing off in over 80% of participants (P < .001).
primary endpointTitle: Ocrelizumab Wearing-Off Phenomenon: Prevalence, Predictors, and Outcomes After Intervention.
findingsRESULTS: Wearing off was observed in 24.8% of 528 people with MS receiving ocrelizumab, most often characterized by worsening residual focal symptoms (79.4%) and fatigue (67.2%).
populationCONCLUSIONS: Wearing off was observed in nearly a quarter of people with MS receiving ocrelizumab.
limitationsTitle: Ocrelizumab Wearing-Off Phenomenon: Prevalence, Predictors, and Outcomes After Intervention.
peer reviewedPublication types: Journal Article
subjectsMETHODS: Clinical records of people with MS receiving ocrelizumab were reviewed to collect demographic variables, clinical characteristics, comorbidities, presence of wearing off and its specific symptoms, and responses after interventions to wearing off.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.